1. | Details of PDMR/person closely associated with them ('PCA') | ||||
a) | Name | Deborah Waterhouse | |||
b) | Position/status | CEO, ViiV Healthcare and President, GSK Global Health | |||
| c) | Initial notification/amendment | Initial notification | |||
2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
a) | Name | GSK plc | |||
b) | LEI | 5493000HZTVUYLO1D793 | |||
3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | ||||
| a) | Description of the financial instrument | Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63 | |||
| b) | Nature of the transaction | Following the vesting on 10 February 2024 of 50% of an award made on 10 February 2021 under the GlaxoSmithKline Deferred Investment Award Programme, Deborah Waterhouse will receive a cash payment of £756,962.38 less applicable tax withholding in respect of 45,600.144 notional Ordinary Shares. | |||
| c) | Price(s) and volume(s) | Price(s) | Volume(s) | ||
| £16.60 | 45,600.144 | ||||
| d) | Aggregated information | N/A (single transaction) | |||
Aggregated volume Price | |||||
e) | Date of the transaction | 2024-02-10 | |||
| f) | Place of the transaction | N/A | |||
| 1. | Details of PDMR/person closely associated with them ('PCA') | ||||
a) | Name | Regis Simard | |||
b) | Position/status | President, Global Supply Chain | |||
| c) | Initial notification/amendment | Initial notification | |||
2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
a) | Name | GSK plc | |||
b) | LEI | 5493000HZTVUYLO1D793 | |||
3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | ||||
| a) | Description of the financial instrument | Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63 | |||
| b) | Nature of the transaction | Following the vesting on 10 February 2024 of 50% of an award made on 10 February 2021 under the GlaxoSmithKline Deferred Investment Award Programme, Regis Simard will receive a cash payment of £378,481.19 less applicable tax withholding in respect of 22,800.072 notional Ordinary Shares. | |||
| c) | Price(s) and volume(s) | Price(s) | Volume(s) | ||
| £16.60 | 22,800.072 | ||||
| d) | Aggregated information | N/A (single transaction) | |||
Aggregated volume Price | |||||
e) | Date of the transaction | 2024-02-10 | |||
| f) | Place of the transaction | N/A | |||
1. | Details of PDMR/person closely associated with them ('PCA') | ||||
a) | Name | Luke Miels | |||
b) | Position/status | Chief Commercial Officer | |||
| c) | Initial notification/amendment | Initial notification | |||
2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
a) | Name | GSK plc | |||
b) | LEI | 5493000HZTVUYLO1D793 | |||
3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | ||||
| a) | Description of the financial instrument | Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63 | |||
| b) | Nature of the transaction | Following the vesting on 10 February 2024 of 50% of an award made on 10 February 2021 under the GlaxoSmithKline Deferred Investment Award Programme, Luke Miels will receive a cash payment of £756,962.38 less applicable tax withholding in respect of 45,600.144 notional Ordinary Shares. | |||
| c) | Price(s) and volume(s) | Price(s) | Volume(s) | ||
| £16.60 | 45,600.144 | ||||
| d) | Aggregated information | N/A (single transaction) | |||
Aggregated volume Price | |||||
e) | Date of the transaction | 2024-02-10 | |||
| f) | Place of the transaction | N/A | |||
| GSK plc | |
| (Registrant) | |
| Date: February 13, 2024 | |
By:/s/ VICTORIA WHYTE -------------------------- | |
| Victoria Whyte | |
| Authorised Signatory for and on | |
| behalf of GSK plc |
